NeoGenomics, Inc.
NEONASDAQHealthcare● Active
$10.95
+$0.05(+0.46%)
Market Cap$285163798
P/E Ratio—
52W High$13.74
52W Low$4.72
NeoGenomics, Inc. (NEO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NEO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
$0.01
Est. $0.01 · +73.0%
Revenue
$0.19B
Est. $0.18B · +1.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
NEO reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.03 | — | — | — | $0.20B | — |
| ▲ Q2 FY2026 | Apr 28, 2026 | $0.01 | $0.01 | +73.0% | $0.19B | $0.18B | +1.2% |
| ▲ Q1 FY2026 | Feb 17, 2026 | $0.04 | $0.06 | +50.0% | $0.19B | $0.19B | +0.9% |
| ▲ Q4 FY2025 | Oct 28, 2025 | $0.02 | $0.03 | +50.0% | $0.19B | $0.19B | -0.2% |
| — Q3 FY2025 | Jul 29, 2025 | $0.03 | $0.03 | +0.0% | $0.18B | $0.18B | -1.4% |
| ▼ Q2 FY2025 | Apr 29, 2025 | -$0.02 | -$0.08 | -300.0% | $0.17B | $0.18B | -8.1% |
| ▲ Q1 FY2025 | Feb 18, 2025 | $0.03 | $0.04 | +33.3% | $0.17B | $0.17B | -0.3% |
| ▲ Q4 FY2024 | Nov 5, 2024 | $0.01 | $0.05 | +316.7% | $0.17B | $0.17B | -3.0% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Beat
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+73.0%
Revenue
$0.19B
Q1 FY2026
Feb 17, 2026Beat
EPS Actual
$0.06
EPS Est.
$0.04
EPS Surpr.
+50.0%
Revenue
$0.19B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
$0.03
EPS Est.
$0.02
EPS Surpr.
+50.0%
Revenue
$0.19B
Q3 FY2025
Jul 29, 2025
EPS Actual
$0.03
EPS Est.
$0.03
EPS Surpr.
+0.0%
Revenue
$0.18B
Q2 FY2025
Apr 29, 2025Miss
EPS Actual
-$0.08
EPS Est.
-$0.02
EPS Surpr.
-300.0%
Revenue
$0.17B
Q1 FY2025
Feb 18, 2025Beat
EPS Actual
$0.04
EPS Est.
$0.03
EPS Surpr.
+33.3%
Revenue
$0.17B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
$0.05
EPS Est.
$0.01
EPS Surpr.
+316.7%
Revenue
$0.17B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.16 | $0.16 | $0.16 | 5 |
| Q3 FY2028 | $0.12 | $0.12 | $0.13 | 5 |
| Q2 FY2028 | $0.11 | $0.11 | $0.11 | 6 |
| Q1 FY2028 | $0.12 | $0.13 | $0.13 | 3 |
| Q4 FY2027 | $0.13 | $0.13 | $0.13 | 2 |
| Q3 FY2027 | $0.09 | $0.09 | $0.09 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.3B | $0.3B | $0.3B | 4 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 4 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 5 |
| Q1 FY2028 | $0.2B | $0.2B | $0.2B | 2 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 28, 2026 | +73.0% | $8.61 | $9.02 | +4.76% |
| ▲ Q1 FY2026 | Feb 17, 2026 | +50.0% | $11.38 | $11.44 | +0.53% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +50.0% | $10.16 | $9.92 | -2.36% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +0.0% | $6.46 | $5.25 | -18.73% |
| ▼ Q2 FY2025 | Apr 29, 2025 | -300.0% | $9.97 | $6.58 | -34.00% |
| ▲ Q1 FY2025 | Feb 18, 2025 | +33.3% | $14.42 | $12.41 | -13.94% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +316.7% | $14.14 | $14.93 | +5.59% |
| ▲ Q3 FY2024 | Jul 29, 2024 | +880.4% | $14.88 | $14.64 | -1.61% |
Q2 FY2026+4.76%
Report Date
Apr 28, 2026
EPS Beat/Miss
+73.0%
Price Before
$8.61
Price After
$9.02
Q1 FY2026+0.53%
Report Date
Feb 17, 2026
EPS Beat/Miss
+50.0%
Price Before
$11.38
Price After
$11.44
Q4 FY2025-2.36%
Report Date
Oct 28, 2025
EPS Beat/Miss
+50.0%
Price Before
$10.16
Price After
$9.92
Q3 FY2025-18.73%
Report Date
Jul 29, 2025
EPS Beat/Miss
+0.0%
Price Before
$6.46
Price After
$5.25
Q2 FY2025-34.00%
Report Date
Apr 29, 2025
EPS Beat/Miss
-300.0%
Price Before
$9.97
Price After
$6.58
Q1 FY2025-13.94%
Report Date
Feb 18, 2025
EPS Beat/Miss
+33.3%
Price Before
$14.42
Price After
$12.41
Q4 FY2024+5.59%
Report Date
Nov 5, 2024
EPS Beat/Miss
+316.7%
Price Before
$14.14
Price After
$14.93
Q3 FY2024-1.61%
Report Date
Jul 29, 2024
EPS Beat/Miss
+880.4%
Price Before
$14.88
Price After
$14.64
Avg Beat Reaction-3.68%
Avg Miss Reaction-34.00%
Beat Rate7 / 8 quarters
Largest Move-34.00% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NEO ends December
NeoGenomics, Inc. (NEO) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $0.01 — beating the analyst consensus of $0.01 by +73.0%. NEO has beaten EPS estimates for 4 consecutive quarters. The next NEO earnings date is expected around September 1, 2026.
Each quarter, investors track NEO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NEO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NEO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NEO earnings · 5 questionsNeoGenomics, Inc.'s next earnings report is expected around September 1, 2026. NEO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NEO historically reports after market close (AMC).
NEO earnings datewhen is NEO earningsNEO next earnings datewhen does NEO report earningsNEO earnings calendar
▸ Source: FMP · NeoGenomics, Inc. SEC filings · US GAAP · NeoGenomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026